课题基金 / 基金详情

Antibiotic resistant genes and resistant phenotypes in MRSA and VISA strains

Antibiotic resistant genes and resistant phenotypes in MRSA and VISA strains
MRSA 和 VISA 菌株中的抗生素耐药基因和耐药表型
批准号:
7987209
负责人:
ALEXANDER TOMASZ
金额:
$58.09万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-03-01 至 2015-04-30

项目摘要

项目成果

ALEXANDER TOMASZ的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):MRSA和VISA菌株继续对葡萄球菌疾病的治疗提出严重挑战。在社区获得性MRSA中出现了高毒力和流行谱系,临床文献中继续报道万古霉素治疗失败。至于耐药金黄色葡萄球菌带来的科学挑战:虽然已经确定了耐药机制的几个关键遗传决定因素,但在MRSA和VISA菌株中,从耐药基因到抗生素耐药表型的途径仍然是一个谜。所有临床分离的MRSA都携带相同的编码低抗生素亲和力蛋白PBP2a的mecA基因。然而,单个MRSA菌株表现出广泛的奥西林MIC值,可以从几微克扩散到毫克范围。此外,大多数MRSA分离株表现出一种特殊的异质表型:这些菌株产生的培养物中,绝大多数细胞(99-99.9%)表现出非常低的MIC值,但同样的培养物也含有一个或多个高耐药细菌亚群,这些亚群以低而独特的频率存在。除了提出一个有趣的科学难题外,异源耐药现象也可能具有重要的临床意义,因为体内高度耐药亚群的选择可能危及治疗的成功。这些复杂的MRSA表型是由相同的mecA决定因素产生的机制尚不清楚。同样,与VISA型万古霉素耐药性获得相关的遗传决定因素最近已通过全基因组测序确定,但万古霉素MIC值增加和大量表型改变是由在测序的VISA菌株JH9[2] -中鉴定的33个特定突变产生的机制仍有待确定。因此,在新的研究项目中,MRSA和VISA机制提出的共同问题是:一个人是如何从抗性基因转变为抗性表型的?新研究计划中的研究被组织成四个主要的活动焦点。项目A.异源耐药MRSA克隆中高水平抗生素耐药性的遗传决定因素。项目b:确定MRSA耐药表型的遗传和环境因素。项目c: MRSA细胞壁合成途径及耐药水平。项目四:降低万古霉素敏感性的遗传途径。
英文摘要
DESCRIPTION (provided by applicant): MRSA and VISA strains continue to present serious challenge to the therapy of staphylococcal disease. Highly virulent and epidemic lineages have emerged among community acquired MRSA and treatment failure during vancomycin therapy continues to be reported in the clinical literature. As to the scientific challenges presented by drug resistant S. aureus: while several critical genetic determinants of the resistance mechanisms have been identified, the path leading from the resistant genes to the antibiotic resistant phenotype has remained an enigma in both MRSA and VISA strains. All clinical isolates of MRSA carry the same mecA gene encoding for the low antibiotic affinity protein PBP2a. Nevertheless, individual MRSA strains exhibit a vast range of oxacillin MIC values which can spread from a few micrograms up to the milligram range. Furthermore, the majority of MRSA isolates show a peculiar - heterogeneous - phenotype: such strains produce cultures in which the great majority of cells (99-99.9%) exhibit very low MIC values but the same cultures also contain one or more sub-populations of highly resistant bacteria which are present with low and unique frequencies. Besides presenting an intriguing scientific puzzle the phenomenon of hetero resistance may have important clinical implications as well, since selection of the highly resistant subpopulations in vivo may jeopardize the success of therapy. The mechanism by which these complex MRSA phenotypes are generated from the same mecA determinant is unknown. Similarly, genetic determinants associated with the acquisition of VISA type vancomycin resistance has been determined recently by full genome sequencing but the mechanism by which the increased vancomycin MIC value and the large number of phenotypic alterations are generated from the 33 specific mutations identified in the sequenced VISA strain JH9 [2] - remains to be determined. Thus, the common question posed for both the MRSA and VISA mechanisms in the new research program is this: how does one go from a resistance gene to the resistant phenotype? The studies in the new research program are organized into four major foci of activity. Project A. Genetic determinants of high level antibiotic resistance in heteroresistant MRSA clones. Project B. Genetic and environmental factors defining the antibiotic resistant phenotype in MRSA. Project C. Pathways of cell wall synthesis and antibiotic resistance level in MRSA. Project D. Genetic pathways to decreased vancomycin susceptibility. PUBLIC HEALTH RELEVANCE: Multidrug resistant MRSA strains continue to spread both in hospitals and in the community and infections by these "superbugs" were estimated to cause close to 19,000 deaths and billions of dollars in health care costs per year in the USA. Clinical treatment failures with vancomycin - often called the "last resort" antibiotic - have also been described. We plan to use methods of modern science such as whole genome DNA sequencing to understand the mechanisms these dangerous pathogens have invented and to help develop new interventions that could reestablish control over multidrug resistant bacteria.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
S.AUREUS CELL WALLS AND DRUG RESISTANCE IN MRSA AND VRSA
  • 批准号:
    6511030
  • 项目类别:
  • 资助金额:
    $61.1万
  • 财政年份:
    2000
  • 负责人:
    ALEXANDER TOMASZ
  • 依托单位:
Antibiotic resistant genes and resistant phenotypes in MRSA and VISA strains
  • 批准号:
    8260491
  • 项目类别:
  • 资助金额:
    $56.94万
  • 财政年份:
    2000
  • 负责人:
    ALEXANDER TOMASZ
  • 依托单位:
Evolution and acquistion of drug resistance in MRSA
  • 批准号:
    7046876
  • 项目类别:
  • 资助金额:
    $53.01万
  • 财政年份:
    2000
  • 负责人:
    ALEXANDER TOMASZ
  • 依托单位:
Antibiotic resistant genes and resistant phenotypes in MRSA and VISA strains
  • 批准号:
    8063919
  • 项目类别:
  • 资助金额:
    $57.64万
  • 财政年份:
    2000
  • 负责人:
    ALEXANDER TOMASZ
  • 依托单位:
海外基金